Research programme: monoclonal T cell receptors - Eli Lilly/ImmunocoreAlternative Names: ImmTACs - Eli Lilly/Immunocore; Immune Mobilising Monoclonal T Cell Receptor Against Cancer - Eli Lilly/Immunocore
Latest Information Update: 18 Jul 2014
At a glance
- Originator Eli Lilly; Immunocore
- Class Immunoconjugates; Immunoglobulin fusion proteins
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 16 Jul 2014 Early research in Cancer in United Kingdom (unspecified route)
- 16 Jul 2014 Early research in Cancer in USA (unspecified route)